Thumb Arthritis Market Research Report - Global Forecast till 2027

Thumb Arthritis Market Research Report: By Type (Osteoarthritis, Rheumatoid) Diagnosis (Physical Examinations, Imaging, FNA) Treatment (Thumb Exercise, Medication, Surgery) End Users (Hospitals & Clinics, Retail Pharmacies) – Forecast Till 2027

ID: MRFR/MED/3800-HCR | | Region: Global | 90 pages

Thumb Arthritis Market Overview:


During the forecast period 2021-2028, the thumb arthritis market size is expected to exhibit a growth rate of 8.1% CAGR.


Thumb arthritis is also known as carpometacarpal (CMC) joint arthritis. This is a common type of arthritis that affects the hands. The joint in the thumb is called the saddle joint. This is the breakdown of the cartilage in the CMC joint of the thumb which irritates the joints. The few symptoms of the disease are thumb joint pain, thumb base swelling, an enlarged or bony appearance of the joint at your thumb base, reduces strength when pinching or gripping other objects, and others. As the rise of humans age, the cartilage wears down which is the second-most common type of arthritis called degenerative arthritis. Lupus or Rheumatoid arthritis may also cause joints to break down.


If the saddle joint doesn’t let the thumb pivot, swivel, or grip things anymore is expected that arthritis is developing in the body. The previous injuries or fractures to the thumb may also cause arthritis to develop in the body. This condition needs the thumb arthritis test. The treatment of thumb arthritis involves a combination of medication and splints. The severe arthritis conditions to the thumb might require surgery. The affecting of arthritis is 10 to 20 times more in women above 50 years compared to men. The World Health Organization (WHO) report states that in 2016, nearly 1.9 billion adults were estimated to be overweight for 650 million obese people. And the geriatric population in 2015 is 900 million and is anticipated to reach 2 billion by 2050.


COVID-19 Analysis:


The COVID-19 outbreak is severely impacted all the business sectors across the globe. The coronavirus spread from one country to another and hit all the people’s lives. To curb the spread of the virus, various country’s governments are implemented stringent regulations like lockdowns, transportation bans, manufacturing industries shut down, public sectors off, etc. Due to the lockdowns, the manufacturing industries face a lot of issues like lack of raw material, shortage of manpower, supply chain disruptions, etc., lead to halting production.


The thumb arthritis market is also negatively impacted by the pandemic. As per the regulations of lockdown, people stay in their homes, and hospitals are filled with corona positive cases results in reducing the visiting to hospital for treating other diseases. Hence the demand for the thumb arthritis market is declined in the first two-quarters of the pandemic. After that, rapidly the growth of the market increases.


Market Dynamics:


Drivers:


The growing prevalence of thumb arthritis is the major factor driving the thumb arthritis market growth. The rising geriatric and obese populations coupled with healthcare expenditure are expected to propel the growth of the market in the review period.


Restraint:


The surgical therapeutics related to thumb arthritis costs are very high and this surgery may occur a few complications which are restraining the market growth.


Opportunities:


Increasing the investment in the research & development activities, introducing innovations in the treatment of thumb arthritis may create an opportunity to boost the market growth. Using biomarkers for identifying patients who can respond to specific medical therapies is expected to increase treatment response rates and reduce the risk of exposure to therapies which makes patients not affected by the side effects of treatment.


Challenges:


Lack of awareness among the people regarding the causes and symptoms of thumb arthritis is the major challenge of the market growth.


Study Objectives -


To provide detailed information about the thumb arthritis market structure along with various forecast segments and sub-segments for the next 7 years.



  • To provide the factors that are impacting the growth of the thumb arthritis market value.

  • To study the thumb arthritis market industry analysis based on porter’s five force analysis, factors-price analysis, etc.

  • To provide previous and future revenue segments and sub-segments of the thumb arthritis market revenue for the four main geographies.

  • To offer the country-level analysis of the present market size and forecast perspective. 

  • To provide country-level analysis of the thumb arthritis industry growth by region, diagnosis, treatment, form, and application.

  • To provide a deep profile of the major enterprises in the market, examine their core competencies, statistics, and draw a global market growth landscape.

  • To evaluate new product developments, strategic alliances, acquisitions, and global market research.


Segment Overview:


The global thumb arthritis market has been divided into five segments based on type, diagnosis, treatment, end-user, and region.


Based on Type


The thumb arthritis types are bifurcated into osteoarthritis thumb arthritis, rheumatoid thumb arthritis, and others.


Based on Diagnosis


The thumb arthritis market diagnosis is classified into various types as imaging, physical examinations, fine needle aspiration (FNA), and others.


Based on Treatment


The thumb arthritis treatment is categorized into a few types as thumb exercise, medication, surgery, and others.


Based on End-user


The thumb arthritis market by end-user is analyzed into a few types as research organizations, hospitals & clinics, retail pharmacies, and others. Among them, the hospitals & clinics segment is holding the largest share due to the high volume of patients visiting hospitals & clinics for the treatment of arthritis, and arthritis therapeutics are available in these pharmacies. Some hospitals provide reimbursements on hospital pharmacy purchases.


Based on Region


Region-wise, the global thumb arthritis market is divided into four main geographies like Asia-Pacific, Americas, Europe, and the Middle East & Africa. Out of these regions, the Americas is accounting for the largest market share due to a well-developed healthcare sector, increasing geriatric population, and rising healthcare expenditure.


Regional Analysis -


Geographically, the thumb arthritis market based on regions is segmented into four main regions as Americas, Asia-Pacific, Europe, and the Middle East & Africa. Among them, the Americas is holding the highest market share due to a growing geriatric population, well-developed healthcare sector, and increasing healthcare expenditure. The presence of developed economies like the U.S and Canada are propelling the market growth in this region.


Owing to the availability of funds for research and rising surgery adoption rates along with the increasing patient population, Europe is holding the second leading position in the market. Additionally, increasing R & D expenses in the therapeutics of the diseases by local players are enhancing the market growth in this region.


Due to the growing geriatric and obese population around the world, Asia-Pacific is witnessed to be the fastest-growing region. The presence of developing economies like India and China with expanding healthcare sector is fuelling the market growth in this region. Due to the poor availability of healthcare services and low per capita healthcare expenditures, the Middle East & Africa is holding the least market share.


Competitive Landscape


The prominent key players in the thumb arthritis market outlook are the following:



  • AbbVie Inc. (U.S)

  • Pfizer Inc. (U.S)

  • BioPro (U.S)

  • F.Hoffmann-La Roche Ltd (Switzerland)

  • General Electric Company (U.K)

  • McKie Splints (U.S)

  • Amgen Inc.(U.S)

  • Carestream Health (U.S) and others.


Recent Developments



  • A popular key player, Anika Therapeutics Inc. provides MONOVISC which is a single injection viscosupplement that is composed of cross-linked sodium hyaluronate in phosphate-buffered saline solution. This is used to treat joint pain related to osteoarthritis.

  • In 2020, in the US, the most famous enterpriser, Glaxosmithkline Plc introduced Voltaren.

  • In 2020, one of the leading companies, Horizon Therapeutics Plc (UK) expanded its presence in the US.


Report Overview:


This global thumb arthritis market research includes the Market Overview, COVID-19 analysis, Market Dynamics, Study Objectives, Segment Overview, Regional Analysis, Competitive Landscape, Recent developments, Segmentation Table, and FAQs. The market scenario includes the market drivers, restraints, challenges, and opportunities. The Thumb Arthritis market forecast segments into five forms as type, diagnosis, treatment, end-user, and region.


Segmentation Table


The thumb arthritis market trends have been segmented into five forms globally based on the type, diagnosis, treatment, end-user, and region.


By Type


Osteoarthritis thumb arthritis, rheumatoid thumb arthritis, and others are a few types of the market.


By Diagnosis


Imaging, physical examinations, fine needle aspiration (FNA), and others are various diagnoses of the market.


By Treatment


Thumb exercise, medication, surgery, and others are a few types of treatments.


By End-user


Research organizations, hospitals & clinics, retail pharmacies, and others are a few end-users.


By Region


Asia-Pacific, Europe, America, and the Middle East & Africa are the four main geographies included in the global market.


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   8.1% (2018-2025)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   BioPro (U.S.), McKie Splints (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Carestream Health. (U.S.), General Electric Company (U.K), and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Growing geriatric and obese population
  • Rising healthcare expenditure


  • Speak to Analyst Ask for Customization

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope Of The Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Diagnosis Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power Of Suppliers

    5.1.2 Bargaining Power Of Buyers

    5.1.3 Threat Of New Entrants

    5.1.4 Threat Of Substitutes

    5.1.5 Intensity Of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Thumb Arthritis Market, By Type

    6.1 Introduction

    6.2 Osteoarthritis Thumb Arthritis

    Market Estimates & Forecast, 20120– 2027

    6.3 Rheumatoid Thumb Arthritis

    Market Estimates & Forecast, 20120– 2027

    6.4 Others

    Chapter 7. Global Thumb Arthritis Market, By Diagnosis

    7.1 Introduction

    7.2 Physical Examinations

    Market Estimates & Forecast, 20120– 2027

    7.3 Imaging

    Market Estimates & Forecast, 20120– 2027

    7.3.1 X-Ray

    7.3.2 Computed Tomography (CT)

    7.3.3 Magnetic Resonance Imaging (MRI)

    7.3.4 Others

    7.4 Fine Needle Aspiration (FNA)

    Market Estimates & Forecast, 20120– 2027

    7.5 Others

    Chapter 8. Global Thumb Arthritis Market, By Treatment

    8.1 Introduction

    8.2 Thumb Exercise

    Market Estimates & Forecast, 20120– 2027

    8.3 Medication

    Market Estimates & Forecast, 20120– 2027

    8.3.1 OCT Medications

    8.3.1.1 Acetaminophen

    8.3.1.2 Ibuprofen

    8.3.1.3 Others

    8.3.2 Prescription Medications

    8.3.2.1 Celecoxib

    8.3.2.2 Meloxicam

    8.3.2.3 Others

    8.4 Surgery

    8.4.1 Trapeziectomy

    8.4.2 Osteotomy

    8.4.3 Others

    8.5 Others

    Chapter 9. Global Thumb Arthritis Market, By End Users

    9.1 Introduction

    9.2 Hospitals & Clinics

    Market Estimates & Forecast, 20120– 2027

    9.3 Research Organizations

    Market Estimates & Forecast, 20120– 2027

    9.4 Retail Pharmacies

    Market Estimates & Forecast, 20120– 2027

    9.5 Others

    Chapter 10. Global Thumb Arthritis Market, By Region

    10.1 Introduction

    10.2 America

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K

    10.3.1.6 Rest Of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic Of Korea

    10.4.6 Rest Of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest Of The Middle East & Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 BioPro

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 McKie Splints

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 AbbVie Inc.

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 F. Hoffmann-La Roche Ltd

    12.4.1 Company Overview

    12.4.2 Product/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Amgen Inc.

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial Overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Pfizer Inc.

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Carestream Health

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 General Electric Company

    12.8.1 Overview

    12.8.2 Product Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs Of The Market

    13.2 Key Companies To Watch

    13.3 Prediction Of Thumb Arthritis Market

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Thumb Arthritis Industry Synopsis, 20120– 2027

    Table 2 Global Thumb Arthritis Market Estimates And Forecast, 20120– 2027, (USD Million)

    Table 3 Global Thumb Arthritis Market By Region, 20120– 2027, (USD Million)

    Table 4 Global Thumb Arthritis Market By Type, 20120– 2027, (USD Million)

    Table 5 Global Thumb Arthritis Market By Diagnosis, 20120– 2027, (USD Million)

    Table 6 Global Thumb Arthritis Market By Treatment, 20120– 2027, (USD Million)

    Table 7 Global Thumb Arthritis Market By End Users, 20120– 2027, (USD Million)

    Table 8 North America Thumb Arthritis By Type, 20120– 2027, (USD Million)

    Table 9 North America Thumb Arthritis By Diagnosis, 20120– 2027, (USD Million)

    Table 10 North America Thumb Arthritis By Treatment, 20120– 2027, (USD Million)

    Table 11 North America Thumb Arthritis By End Users, 20120– 2027, (USD Million)

    Table 12 U.S. Thumb Arthritis By Type, 20120– 2027, (USD Million)

    Table 13 U.S. Thumb Arthritis By Diagnosis, 20120– 2027, (USD Million)

    Table 14 U.S. Thumb Arthritis By Treatment, 20120– 2027, (USD Million)

    Table 15 U.S. Thumb Arthritis By End Users, 20120– 2027, (USD Million)

    Table 16 Canada Thumb Arthritis By Type, 20120– 2027, (USD Million)

    Table 17 Canada Thumb Arthritis By Diagnosis, 20120– 2027, (USD Million)

    Table 18 Canada Thumb Arthritis By Treatment, 20120– 2027, (USD Million)

    Table 19 Canada Thumb Arthritis By End Users, 20120– 2027, (USD Million)

    Table 20 South America Thumb Arthritis By Type, 20120– 2027, (USD Million)

    Table 21 South America Thumb Arthritis By Diagnosis, 20120– 2027, (USD Million)

    Table 22 South America Thumb Arthritis By Treatment, 20120– 2027, (USD Million)

    Table 23 South America Thumb Arthritis By End Users, 20120– 2027, (USD Million)

    Table 24 Europe Thumb Arthritis By Type, 20120– 2027, (USD Million)

    Table 25 Europe Thumb Arthritis By Diagnosis, 20120– 2027, (USD Million)

    Table 26 Europe Thumb Arthritis By Treatment, 20120– 2027, (USD Million)

    Table 27 Europe Thumb Arthritis By End Users, 20120– 2027, (USD Million)

    Table 28 Western Europe Thumb Arthritis By Type, 20120– 2027, (USD Million)

    Table 29 Western Europe Thumb Arthritis By Diagnosis, 20120– 2027, (USD Million)

    Table 30 Western Europe Thumb Arthritis By Treatment, 20120– 2027, (USD Million)

    Table 31 Western Europe Thumb Arthritis By End Users, 20120– 2027, (USD Million)

    Table 32 Eastern Europe Thumb Arthritis By Type, 20120– 2027, (USD Million)

    Table 33 Eastern Europe Thumb Arthritis By Diagnosis, 20120– 2027, (USD Million)

    Table 34 Eastern Europe Thumb Arthritis By Treatment, 20120– 2027, (USD Million)

    Table 35 Eastern Europe Thumb Arthritis By End Users, 20120– 2027, (USD Million)

    Table 36 Asia Pacific Thumb Arthritis By Type, 20120– 2027, (USD Million)

    Table 37 Asia Pacific Thumb Arthritis By Diagnosis, 20120– 2027, (USD Million)

    Table 38 Asia Pacific Thumb Arthritis By Treatment, 20120– 2027, (USD Million)

    Table 39 Asia Pacific Thumb Arthritis By End Users, 20120– 2027, (USD Million)

    Table 40 Middle East & Africa Thumb Arthritis By Type, 20120– 2027, (USD Million)

    Table 41 Middle East & Africa Thumb Arthritis By Diagnosis, 20120– 2027, (USD Million)

    Table 42 Middle East & Africa Thumb Arthritis By Treatment, 20120– 2027, (USD Million)

    Table 43 Middle East & Africa Thumb Arthritis By End Users, 20120– 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation For Global Thumb Arthritis Market

    Figure 3 Market Dynamics For Global Thumb Arthritis Market

    Figure 4 Global Thumb Arthritis Market Share, By Type 2020

    Figure 5 Global Thumb Arthritis Market Share, By Diagnosis 2020

    Figure 6 Global Thumb Arthritis Market Share, By Treatment, 2020

    Figure 7 Global Thumb Arthritis Market Share, By End Users, 2020

    Figure 8 Global Thumb Arthritis Market Share, By Region, 2020

    Figure 9 North America Thumb Arthritis Share, By Country, 2020

    Figure 10 Europe Thumb Arthritis Share, By Country, 2020

    Figure 11 Asia Pacific Thumb Arthritis Share, By Country, 2020

    Figure 12 Middle East & Africa Thumb Arthritis Share, By Country, 2020

    Figure 13 Global Thumb Arthritis Market: Company Share Analysis, 2020 (%)

    Figure 14 BioPro: Key Financials

    Figure 15 BioPro: Segmental Revenue

    Figure 16 BioPro: Geographical Revenue

    Figure 17 McKie Splints: Type UK Ltd: Key Financials

    Figure 18 McKie Splints: Type UK Ltd: Segmental Revenue

    Figure 19 McKie Splints: Type UK Ltd: Geographical Revenue

    Figure 20 AbbVie Inc.: Key Financials

    Figure 21 AbbVie Inc.: Segmental Revenue

    Figure 22 AbbVie Inc.: Geographical Revenue

    Figure 23 F. Hoffmann-La Roche Ltd: Key Financials

    Figure 24 F. Hoffmann-La Roche Ltd: Segmental Revenue

    Figure 25 F. Hoffmann-La Roche Ltd: Geographical Revenue

    Figure 26 Amgen Inc.: Key Financials

    Figure 27 Amgen Inc.: Segmental Revenue

    Figure 28 Amgen Inc.: Geographical Revenue

    Figure 29 Pfizer Inc.: Key Financials

    Figure 30 Pfizer Inc.: Segmental Revenue

    Figure 31 Pfizer Inc.: Geographical Revenue

    Figure 32 Carestream Health: Key Financials

    Figure 33 Carestream Health: Segmental Revenue

    Figure 34 Carestream Health: Geographical Revenue

    Figure 35 General Electric Company: Key Financials

    Figure 36 General Electric Company: Segmental Revenue

    Figure 37 General Electric Company: Geographical Revenue